Figure 1.
Study plan stratified according to treatment site, HIV status and severity of adverse drug reactions.
Table 1.
Definitions used to grade, identify and classify adverse events.
Table 2.
Specific drugs, the dosages used in XDR-TB treatment regimens, and the frequency of drug withdrawal due to adverse events relative to the number of patients prescribed the drug.
Table 3.
Socio-demographic and treatment related clinical characteristics of 115 patients who initiated treatment for extensively drug-resistant tuberculosis (XDR-TB).
Figure 2.
Kaplan-Meier probabilities of XDR-TB culture-conversion in: (A) The whole cohort of patients who experienced AEs stratified by severity score i.e. none or mild to moderate (grade 0, 1 and 2; dashed line) versus severe (grade 3 to 5; solid line); (B) HIV-infected patients whom experienced AEs stratified by stratified by severity score; (C) HIV-uninfected patients who experienced AEs stratified by stratified by severity score, and Kaplan-Meier probabilities of death: (D) The whole cohort of patients from the date of treatment-initiation, (E) HIV-infected patients who experienced AEs stratified by severity score, and (F) HIV-uninfected patients who experienced AEs stratified by severity categories.
Table 4.
Univariate and multivariate analysis of factors associated with mortality in 115 patients with XDR-TB.
Table 5.
Type of adverse event that occurred (n = 161) and total number of patients experiencing these adverse events (n = 115) in patients from the Western Cape, Northern Cape and Gauteng provinces who initiated treatment for XDR-TB.
Table 6.
Effect of TB strain type on AEs stratified by Beijing and non-Beijing strain type.